Completed NA INTERVENTIONAL 2-arm NCT06154408

Evaluating the Impact of Omega-3 Fatty Acid Supplementation (Soloways™) on Lipid Profiles in Adults With PPARG Polymorphisms (SOLIPARG)

Evaluating the Impact of Omega-3 Fatty Acid Supplementation (Soloways™) on Lipid Profiles in Adults With PPARG Polymorphisms: A Randomized, Double-blind, Placebo-controlled Trial

Sponsor: Center of New Medical Technologies

Conditions LDL Hyperlipoproteinemia Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia Triglyceride Storage Type I or II Disease

Interventions Placebo omega-3 fatty acids

Updated 5 times since 2024 Last updated: Mar 17, 2025 Started: Feb 10, 2022 Primary completion: Jul 1, 2022 Completion: Nov 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on LDL Hyperlipoproteinemia and Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia, this trial is completed. The trial is conducted by Center of New Medical Technologies and has accumulated 5 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Apr 2025 — Sep 2025 [monthly]

Completed NA
Sep 2024 — Apr 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2024 — Jul 2024 [monthly]

Completed NA

First recorded

Feb 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Center of New Medical Technologies
S.LAB (SOLOWAYS)
Triangel Scientific

Data source: S.LAB (SOLOWAYS)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Novosibirsk, Russia